Following a Freedom of Information request, CBD-Intel has ascertained that according to EU authorities cannabidiol and other extracts of cannabis could be deemed illegal as an ingredient in cosmetics.
The United States Food and Drug Administration Modernization Act of 1997(FDAMA) amended the Federal Food, Drug, and Cosmetic Act. This act is related to the regulation of food, drugs, devices, and biological products by the FDA.
On December 20, 2018, The Hemp Farming Act of 2018, S. 2667 (2018 Hemp Bill) became law and formally and definitively removed hemp from the list of controlled substances. The 2018 Hemp Bill redefines hemp as all parts of the Cannabis Sativa plant that do not exceed 0.3% delta-9 THC by dry weight, including “derivatives,” “extracts” and “cannabinoids.”14 Importantly, the 2018 Hemp Bill explicitly removes popular hemp products, including hemp-derived CBD, from the purview of the CSA.
In addition to industrial hemp, CBD may also be lawful if it is derived from “non-psychoactive hemp” imported into the US. Non-psychoactive hemp is the term used by the Ninth Circuit Court of Appeals in a pair of companion cases filed against the DEA by a national trade organization, the Hemp Industries Association (HIA), regarding a DEA rule, which would have made it illegal to import any hemp products that contained any THC, including trace amounts.16,17 In a February 6, 2004 ruling, the Court found that the DEA had exceeded its authority in enacting the rule and struck it down as void and unenforceable.18
Changes on the medicinal usage of cannabis and cannabis-related
substances While EIHA’s main mission is to represent interests of the industrial hemp community, we also welcome breakthrough recommendations of WHO on cannabis, cannabis-related substances and pharmaceutical preparations. These decisions finally remove from cannabis a stigma of one of the most dangerous substances without any medicinal value. Proposal to delete cannabis and cannabis resin from Schedule IV of the Single Convention on Narcotic Drugs (1961) means that therapeutic potential cannabis has been reclaimed and scientific research will become more widespread. The inclusion of preparations containing cannabis and natural and synthetic cannabinoids to Schedule III is a clear token of their low abuse potential with much-eased access of patients to innovative medicinal products.
Today hemp is a niche crop, cultivated on more than 33,000 ha in the European Union (2016). Because of its unique properties, particularly its environmental benefits and the high yield of natural technical fibres, hemp is a valuable crop for the bio-based economy.
81,544 Acres 2016